These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 21106864)

  • 21. Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
    Jellinger PS
    Postgrad Med; 2011 Jan; 123(1):53-65. PubMed ID: 21293084
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.
    Nauck M
    Diabetes Obes Metab; 2016 Mar; 18(3):203-16. PubMed ID: 26489970
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Incretin mimetics and DPP-4 inhibitors: new approach to treatment of type 2 diabetes mellitus.
    Siddiqui NI
    Mymensingh Med J; 2009 Jan; 18(1):113-24. PubMed ID: 19182763
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Incretin-based therapies for type 2 diabetes mellitus.
    Lovshin JA; Drucker DJ
    Nat Rev Endocrinol; 2009 May; 5(5):262-9. PubMed ID: 19444259
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
    Boland CL; Degeeter M; Nuzum DS; Tzefos M
    Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Managing type 2 diabetes: going beyond glycemic control.
    Stolar MW; Hoogwerf BJ; Gorshow SM; Boyle PJ; Wales DO
    J Manag Care Pharm; 2008 Jun; 14(5 Suppl B):s2-19. PubMed ID: 18597582
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Distinguishing among incretin-based therapies. Introduction.
    Campbell RK; Cobble ME; Reid TS; Shomali ME
    J Fam Pract; 2010 Sep; 59(9 Suppl 1):S3-4. PubMed ID: 20824238
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Managing type 2 diabetes in the primary care setting: beyond glucocentricity.
    Kuritzky L
    Am J Med Sci; 2010 Aug; 340(2):133-43. PubMed ID: 20571352
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical efficacy of GLP-1 agonists and their place in the diabetes treatment algorithm.
    Unger J
    J Am Osteopath Assoc; 2011 Feb; 111(2 Suppl 1):eS2-9. PubMed ID: 21389296
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Type 2 diabetes: where we are today: an overview of disease burden, current treatments, and treatment strategies.
    Campbell RK
    J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S3-9. PubMed ID: 19801365
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination pharmacotherapy with incretins: what works best and when?
    Over RK; Ratner RE
    Curr Diab Rep; 2008 Oct; 8(5):361-7. PubMed ID: 18778584
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Emerging incretin based therapies for type 2 diabetes: incretin mimetics and DPP-4 inhibitors.
    Stonehouse A; Okerson T; Kendall D; Maggs D
    Curr Diabetes Rev; 2008 May; 4(2):101-9. PubMed ID: 18473757
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The entero-insular axis: implications for human metabolism.
    Ranganath LR
    Clin Chem Lab Med; 2008; 46(1):43-56. PubMed ID: 18020966
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardiovascular implications of antihyperglycemic therapies for type 2 diabetes.
    Ovalle F
    Clin Ther; 2011 Apr; 33(4):393-407. PubMed ID: 21635987
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evolving treatment strategies for the management of type 2 diabetes.
    Cefalu WT
    Am J Med Sci; 2012 Jan; 343(1):21-6. PubMed ID: 22205062
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clarifying the role of incretin-based therapies in the treatment of type 2 diabetes mellitus.
    Campbell RK
    Clin Ther; 2011 May; 33(5):511-27. PubMed ID: 21665040
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Incretin-based therapies: review of the outpatient literature with implications for use in the hospital and after discharge.
    Bode B; Amin A
    Hosp Pract (1995); 2009 Dec; 37(1):7-21. PubMed ID: 20720383
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.
    Herman GA; Bergman A; Stevens C; Kotey P; Yi B; Zhao P; Dietrich B; Golor G; Schrodter A; Keymeulen B; Lasseter KC; Kipnes MS; Snyder K; Hilliard D; Tanen M; Cilissen C; De Smet M; de Lepeleire I; Van Dyck K; Wang AQ; Zeng W; Davies MJ; Tanaka W; Holst JJ; Deacon CF; Gottesdiener KM; Wagner JA
    J Clin Endocrinol Metab; 2006 Nov; 91(11):4612-9. PubMed ID: 16912128
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Incretin-based therapy of type 2 diabetes mellitus.
    Knop FK; Vilsbøll T; Holst JJ
    Curr Protein Pept Sci; 2009 Feb; 10(1):46-55. PubMed ID: 19275672
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical use.
    Kendall DM; Cuddihy RM; Bergenstal RM
    Am J Med; 2009 Jun; 122(6 Suppl):S37-50. PubMed ID: 19464427
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.